Search results for "virus"

showing 10 items of 5024 documents

Knowledge about infection with human papillomavirus: a systematic review.

2007

Abstract Objective. Human papillomavirus (HPV) is a necessary cause of cervical cancer and genital warts. The aim of this systematic literature review was to provide an overview of knowledge about HPV infection among the public, students, patients and health professionals. Method. PubMed searches were performed and the results of studies were reported by age, gender, study population, country, recruitment score and year of study conduct. The recruitment score covered the mode of recruitment, study size and response rate. Results. We included 39 studies published between 1992 and 2006 covering a total of 19,986 participants. The proportion of participants who had heard of HPV varied from 13%…

medicine.medical_specialtyHealth Knowledge Attitudes PracticeEpidemiologyPopulationUterine Cervical NeoplasmsGenital wartsmedicineHumansPapillomavirus VaccinesRisk factoreducationPapillomaviridaeGynecologyCervical cancerResponse rate (survey)education.field_of_studybusiness.industryPapillomavirus InfectionsPublic Health Environmental and Occupational HealthHPV infectionvirus diseasesmedicine.diseaseSystematic reviewCondylomata AcuminataFamily medicinePopulation studyFemalebusinessPreventive medicine
researchProduct

Wastewater-based epidemiology, a tool to bridge biomarkers of exposure, contaminants, and human health

2021

The concept of wastewater-based epidemiology also known as sewage epidemiology was proposed by Daughton in 2001. Wastewater-based epidemiology has become now a reality that makes it possible to determine consumption or exposure to chemical substances or pathogens in a population by measuring certain compounds (drugs of abuse, metabolites, or biomarkers) or microorganisms (viruses, bacteria, and parasites) in wastewater. The first and most developed application is the estimation of illicit drug consumption in communities or populations, but it can be used to measure both consumption and exposure to a wide range of substances and pathogens. Its recent application to measure the severe acute r…

medicine.medical_specialtyHealth Toxicology and MutagenesisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)0208 environmental biotechnologyPopulationSewage02 engineering and technologyDisease010501 environmental sciences01 natural sciencesHuman healthEnvironmental healthEpidemiologyEnvironmental ChemistryMedicineeducation0105 earth and related environmental scienceseducation.field_of_studybusiness.industryWastewater analysisPublic Health Environmental and Occupational HealthContamination020801 environmental engineeringWastewaterChemicalsPathogensbusinessCommunity health assessmentBiomarkersCurrent Opinion in Environmental Science & Health
researchProduct

Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease – a cohort study…

2021

AbstractAimsPatients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality.Method and resultsWe used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existent heart disease and in-hospital mortality. 16,511 patients with COVID-19 were included (21.1% aged 66 – 75 years; 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male and of…

medicine.medical_specialtyHeart diseaseCoronavirus disease 2019 (COVID-19)business.industryDiseasemedicine.diseasesymbols.namesakeHeart failureInternal medicineRelative riskmedicinesymbolsPoisson regressionPresentation (obstetrics)businessCohort study
researchProduct

Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched

2021

Since molecules with direct-acting antiviral (DAA) became available, the landscape of the treatment of hepatitis C virus (HCV) infection has completely changed. The new drugs are extremely effective in eradicating infection, and treatment is very well tolerated with a duration of 8-12 wk. This review aims to report the outstanding clinical benefits of DAA and to highlight their critical disadvantages, identifying some clinically relevant hot topics. First, do the rates of virological response remain as high when patients with more advanced cirrhosis are considered? Large studies have shown slightly lower but still satisfactory rates of response in these patients. Nevertheless, modified sche…

medicine.medical_specialtyHepatitis B virusHepatitis C virusHepatitis C virus/hepatitis B virus coinfection.HepacivirusHypoglycemiamedicine.disease_causeGastroenterologyAntiviral Agents03 medical and health sciencesLiver diseasechemistry.chemical_compound0302 clinical medicineDiabetes mellitusInternal medicinemedicineAnimalsHumansAdvanced cirrhosisDirect antiviral activityHepatitis B virusbusiness.industryHepatitis C virusCoinfectionIncidence (epidemiology)RibavirinGastroenterologyvirus diseasesMinireviewsGeneral MedicineHepatitis C Chronicmedicine.diseaseHepatitis BHepatitis Cdigestive system diseaseschemistry030220 oncology & carcinogenesisCoinfection030211 gastroenterology & hepatologyNeoplasm Recurrence LocalLiver cancerbusinessLiver cancerChickensWorld Journal of Gastroenterology
researchProduct

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

2005

Background/Aims: Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy. Methods: Retrospective analysis of data from 1121 adults with chronic hepatitis C treated for 48 weeks with peginterferon alfa-2a (40 KD) 180 mu g/week plus placebo or ribavirin (1000/1200 mg/day), or interferon alfa-2b 3 MIU three times/week plus ribavirin in a randomized, multinational, study. Results: 67% of patients treated with peginterferon alfa-2a (40 KD)/ribavirin with early virological responses (HCV RNA negative or >= 2 log(10) decrease) at week 12 had SVRs at week 72 (HCV RNA 80 % of the planned ribavirin dose. Concl…

medicine.medical_specialtyHepatitis B virusviral hepatitisAlpha interferonPeginterferon-alfaInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundpredictabilityInternal medicineRibavirinmedicinechronic hepatitis CHumansProbabilityRetrospective StudiesHepatitis B viruspeginterferon alfa-2a (40 KD)treatmentHepatologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicViral Loadmedicine.diseasedigestive system diseasesRecombinant ProteinsTreatment OutcomechemistryImmunologyRNA ViralDrug Therapy Combinationsustained virological responseViral hepatitisbusinessViral loadPeginterferon alfa-2amedicine.drugJournal of hepatology
researchProduct

Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus

2011

Summary Nearly three-quarters of human immunodeficiency virus–hepatitis C virus (HIV-HCV) coinfected patients in France currently need to be cured of their chronic HCV infection. The increase in sustained virological response rates obtained with the recently available HCV protease inhibitors in treatment-naive genotype-1 patients has generated considerable hope in these co-infected patients. However, several particularities (such as a higher baseline HCV load, more advanced liver fibrosis, frequent co-morbidities, and the risk of toxicity and drug–drug interactions) have not allowed the direct extrapolation of the results observed in HCV-monoinfected patients to patients with HIV-HCV co-inf…

medicine.medical_specialtyHepatitis C virusHuman immunodeficiency virus (HIV)HIV InfectionsContext (language use)medicine.disease_causeAntiviral AgentsViruschemistry.chemical_compoundPegylated interferonFibrosismedicineHumansIntensive care medicineHepatologybusiness.industryRibavirinGastroenterologyvirus diseasesHepatitis C Chronicmedicine.diseasechemistryImmunologyToxicitybusinessAlgorithmsmedicine.drugClinics and Research in Hepatology and Gastroenterology
researchProduct

Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients

2015

The aim of this review was to detail the current therapies and treatments for chronic hepatitis C virus in coinfected patients, focusing on HCV antiviral agents currently used in practice today or scheduled to enter the open market soon. Several direct-acting antiviral (DAA) combinations show high sustained virologic response (SVR) rates in HIV/HCV-coinfected patients, which are often close to those observed in HCV-monoinfected patients. Most recommendations regarding treatment stem from trials with coinfected patients. However, data are lacking for some aspects of HCV-treatment in coinfection, so extrapolations must be made from data obtained predominately from monoinfected patients. HIV/H…

medicine.medical_specialtyHepatitis C virusImmunologyPopulationHuman immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeAntiviral AgentsVirusLiver diseaseChronic hepatitisVirologyInternal medicinemedicineHumansHiv infected patientsDrug Interactionseducationeducation.field_of_studyOncology (nursing)business.industryvirus diseasesHematologyHepatitis C Chronicmedicine.diseasedigestive system diseasesTreatment OutcomeInfectious DiseasesOncologyImmunologyCoinfectionDrug Therapy CombinationbusinessCurrent Opinion in HIV and AIDS
researchProduct

Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort

2017

BACKGROUND AND AIMS: Few data exist on changes to substance use patterns before and after hepatitis C virus (HCV) treatment. We used longitudinal data of HIV-HCV co-infected individuals to examine whether receiving pegylated interferon (Peg-IFN)-based therapy irrespective of HCV clearance could modify tobacco, cannabis and alcohol use. DESIGN: A prospective cohort of HIV-HCV co-infected individuals was enrolled from 2006. Participants' clinical data were retrieved from medical records and socio-demographic and behavioural characteristics were collected by yearly self-administered questionnaires. SETTING: Data were collected across 17 hospitals in France. PARTICIPANTS: All HIV-HCV co-infecte…

medicine.medical_specialtyHepatitis C virusMedicine (miscellaneous)Binge drinkingmedicine.disease_causeUnit of alcohol03 medical and health sciences0302 clinical medicinePegylated interferonInternal medicinemedicine030212 general & internal medicineProspective cohort studybiologybusiness.industryvirus diseasesHepatitis Cmedicine.diseasebiology.organism_classificationVirologydigestive system diseases3. Good healthPsychiatry and Mental healthCohort030211 gastroenterology & hepatologyCannabisbusinessmedicine.drugAddiction
researchProduct

Patient-to-patient transmission of hepatitis C virus (HCV) during colonoscopy diagnosis

2010

Abstract Background No recognized risk factors can be identified in 10-40% of hepatitis C virus (HCV)-infected patients suggesting that the modes of transmission involved could be underestimated or unidentified. Invasive diagnostic procedures, such as endoscopy, have been considered as a potential HCV transmission route; although the actual extent of transmission in endoscopy procedures remains controversial. Most reported HCV outbreaks related to nosocomial acquisition have been attributed to unsafe injection practices and use of multi-dose vials. Only a few cases of likely patient-to-patient HCV transmission via a contaminated colonoscope have been reported to date. Nosocomial HCV infecti…

medicine.medical_specialtyHepatitis C virusMolecular Sequence DataColonoscopyHepacivirusViral Nonstructural Proteinsmedicine.disease_causelcsh:Infectious and parasitic diseaseschemistry.chemical_compoundVirologyEpidemiologyDisease Transmission InfectiousmedicineHumanslcsh:RC109-216NS5BRetrospective StudiesCross InfectionMolecular Epidemiologymedicine.diagnostic_testbusiness.industryTransmission (medicine)ResearchOutbreakRetrospective cohort studyColonoscopySequence Analysis DNAHepatitis Cmedicine.diseaseHepatitis CVirologyInfectious DiseaseschemistryRNA ViralbusinessVirology Journal
researchProduct

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C

2012

Summary.  Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naive patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800–1400  mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44…

medicine.medical_specialtyHepatitis C virusPopulationmacromolecular substancesmedicine.disease_causeGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawVirologyInternal medicineMedicineeducationeducation.field_of_studyHepatologybusiness.industryRibavirintechnology industry and agriculturevirus diseasesmedicine.diseasedigestive system diseasesMenopauseInfectious DiseasesEndocrinologychemistryPropensity score matchingSteatosisMetabolic syndromebusinessJournal of Viral Hepatitis
researchProduct